Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A promising antibody

01.10.2019

Kiel research team tests novel immunotherapy against certain blood cancer cells in preclinical model trials

Acute lymphoblastic leukaemia (ALL) is the most common cancer in children. This form of blood cancer is caused by malignant abnormal precursor cells of certain white blood cells, and usually leads to a rapidly progressive reduction of bone marrow function, and thus impaired blood formation.


Caption: Macrophages, scavenger cells of the immune system, devour tumor cells (colored in green).

© Dr Fotini Vogiatzi


Caption: Tested the antibody daratumumab for possible effectiveness against T-ALL cancer cells: PD Dr Denis Schewe, Dr Fotini Vogiatzi und Dr Lennart Lenk (left to right).

© Christian Urban, Kiel University

If left untreated, it quickly leads to death. Despite the severity of the disease, in many cases children today have good chances of survival and being cured. The current standard treatment consists of various forms of chemotherapy, but these cause severe side-effects because of their toxic effect on healthy cells, too.

In addition, a certain proportion of the young patients - about 15 to 20 percent - do not respond to treatment in a sustained manner. Scientists from the Faculty of Medicine at Kiel University (CAU) and the Department of Pediatric and Adolescent Medicine I at the University Medical Center Schleswig-Holstein (UKSH) Campus Kiel are therefore exploring alternative forms of treatment, in particular different variants of immunotherapy.

In a recent preclinical study, they examined the antibody daratumumab, which has already proven successful against another type of cancer. They hoped for a possible suitability to combat blood cancer cells in a subtype of ALL, the so-called T-cell ALL (T-ALL).

To date, there is no form of immunotherapy for this type of the disease. In model experiments, a complete removal of the cancer cells was achieved in around 50 percent of the cases. Together with their partner research institutions nationwide, the Kiel scientists recently published their latest research results in the renowned scientific journal Blood.

Preclinical model experiments show promising results

In the exploration of new forms of treatment against cancer, immunotherapy with antibodies is among those which show promising potential. This treatment uses artificially produced antibodies, i.e. specific synthetic proteins which work according to the lock-and-key principle. Under certain circumstances, they can help cells of the immune system to recognise and destroy cancer cells.

However, in many cases the exploration of the associated treatment options is still in an early stage. PD Dr Denis Schewe, senior physician for hematology, oncology and stem cell transplantation at the Department of Pediatric and Adolescent Medicine at the UKSH, and his research team carried out fundamental combination experiments on mice using the antibody daratumumab to test for possible effectiveness against T-ALL cancer cells. In doing so, they also compared antibody treatment alone with a combination of antibody and chemotherapy.

"We were able to report initial promising results: half of the animals treated with the antibody showed long term survival, without any signs of disease," explained the Kiel pediatric oncologist Schewe.

It made no difference whether they were treated with the antibody only, or with a combination of chemotherapy and immunotherapy. "The chemotherapy, with its serious side-effects, achieved no improvement, and in the case of our model experiment brought no additional benefits," said Schewe. However, these experimental results are in no way directly transferable to patients. "Therefore, in the further development of antibody treatment for T-ALL, we must continue to investigate in all directions," emphasised Schewe.

Translational focus of Kiel’s oncology

The research activities in Kiel’s pediatric oncology are a good example of how fundamental and clinical research cooperate through the Kiel Oncology Network (KON) established at the CAU. For example, KON member Schewe worked closely with Dr Mildred-Scheel-Haus on a recent study at the USKH.

With its Division of Stem Cell Transplantation and Immunotherapy, it also provides treatment for leukaemia patients. "Our goal is to further optimise the antibody treatment for T-ALL. In the middle of the year, we were able to raise significant funding from the Deutsche Krebshilfe e.V. (German Cancer Aid) for this purpose," said Schewe.

"Dr Schewe’s research on the possibilities of immunotherapy for blood cancers are a good example of the strong translational orientation of our network. The intensive interdisciplinary exchange between researchers, the clinic and researching physicians will also help to develop improved treatment options in the fight against other cancer types in future," emphasised Professor Susanne Sebens from the Institute of Experimental Cancer Research at the CAU and spokesperson of the Kiel Oncology Network.

About the Kiel Oncology Network (KON)
The KON was established in 2013 as part of the CAU’s priority research area Kiel Life Science, with the goal of linking the research activities of as many basic and clinically-orientated oncology researchers as possible, and promoting cooperation between them.

As such, KON incorporates a broad spectrum of long-term and excellent expertise in oncology, including tumour biology, genetics and epigenetics, immunology, pharmacology, pathology, structural biology as well as modern medical imaging. KON's vision is to gain a significantly better understanding of all the important steps in tumour evolution, as well as resistance mechanisms to cancer treatment, by using comprehensive and multidisciplinary analysis strategies.

This knowledge could provide a basis for the development of innovative diagnosis and treatment strategies, to decisively improve the prognosis for and survival of cancer patients.

Photos are available for download at:

https://www.uni-kiel.de/de/pressemitteilungen/2019/294-schewe-blood-group.jpg
Caption: Tested the antibody daratumumab for possible effectiveness against T-ALL cancer cells: PD Dr Denis Schewe, Dr Fotini Vogiatzi und Dr Lennart Lenk (left to right).
© Christian Urban, Kiel University

https://www.uni-kiel.de/de/pressemitteilungen/2019/294-schewe-blood-phagocytosis...
Caption: Macrophages, scavenger cells of the immune system, devour tumor cells (colored in green).
© Dr Fotini Vogiatzi

Press contact:
Christian Urban
Science communication “Kiel Life Science”, Kiel University:
Tel.: +49 (0)431-880-1974
E-mail: curban@uv.uni-kiel.de

More information:

Department of Pediatric and Adolescent Medicine I
Faculty of Medicine, Kiel University / UKSH:
http://www.uksh.de/paediatrie-kiel

Kiel Oncology Network, Faculty of Medicine, Kiel University:
http://www.medizin.uni-kiel.de/de/forschung/forschungsinitiativen/kiel-oncology-...

Division of Stem Cell Transplantation and Immunotherapy,
Dr Mildred-Schweel-Haus, UKSH
http://www.uksh.de/med2-kiel/Sektion+für+Stammzell_+und+Immuntherapie/Dr_+Mildre...

Wissenschaftliche Ansprechpartner:

PD Dr Denis Schewe
Senior physician for hematology, oncology,
stem cell transplantation
Department of Pediatric and Adolescent Medicine I
Faculty of Medicine, Kiel University / UKSH
Tel.: +49 (0)431 500-20140
E-mail: denis.schewe@uksh.de

Originalpublikation:

Fotini Vogiatzi, Dorothee Winterberg, Lennart Lenk, Swantje Buchmann, Gunnar Cario, Martin Schrappe, Matthias Peipp, Paulina Richter-Pechanska, Andreas E Kulozik, Jana Lentes, Anke K Bergmann, Thomas Valerius, Fabian Simon Frielitz, Christian Kellner and Denis M Schewe (2019): Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. Blood
https://doi.org/10.1182/blood.2019000904

Weitere Informationen:

http://www.uksh.de/paediatrie-kiel
http://www.medizin.uni-kiel.de/de/forschung/forschungsinitiativen/kiel-oncology-...
http://www.uksh.de/med2-kiel/Sektion+für+Stammzell_+und+Immuntherapie/Dr_+Mildre...

Dr. Boris Pawlowski | Christian-Albrechts-Universität zu Kiel

More articles from Life Sciences:

nachricht Predicting a protein's behavior from its appearance
10.12.2019 | Ecole Polytechnique Fédérale de Lausanne

nachricht Could dark carbon be hiding the true scale of ocean 'dead zones'?
10.12.2019 | University of Plymouth

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How to induce magnetism in graphene

Graphene, a two-dimensional structure made of carbon, is a material with excellent mechanical, electronic and optical properties. However, it did not seem suitable for magnetic applications. Together with international partners, Empa researchers have now succeeded in synthesizing a unique nanographene predicted in the 1970s, which conclusively demonstrates that carbon in very specific forms has magnetic properties that could permit future spintronic applications. The results have just been published in the renowned journal Nature Nanotechnology.

Depending on the shape and orientation of their edges, graphene nanostructures (also known as nanographenes) can have very different properties – for example,...

Im Focus: Electronic map reveals 'rules of the road' in superconductor

Band structure map exposes iron selenide's enigmatic electronic signature

Using a clever technique that causes unruly crystals of iron selenide to snap into alignment, Rice University physicists have drawn a detailed map that reveals...

Im Focus: Developing a digital twin

University of Texas and MIT researchers create virtual UAVs that can predict vehicle health, enable autonomous decision-making

In the not too distant future, we can expect to see our skies filled with unmanned aerial vehicles (UAVs) delivering packages, maybe even people, from location...

Im Focus: The coldest reaction

With ultracold chemistry, researchers get a first look at exactly what happens during a chemical reaction

The coldest chemical reaction in the known universe took place in what appears to be a chaotic mess of lasers. The appearance deceives: Deep within that...

Im Focus: How do scars form? Fascia function as a repository of mobile scar tissue

Abnormal scarring is a serious threat resulting in non-healing chronic wounds or fibrosis. Scars form when fibroblasts, a type of cell of connective tissue, reach wounded skin and deposit plugs of extracellular matrix. Until today, the question about the exact anatomical origin of these fibroblasts has not been answered. In order to find potential ways of influencing the scarring process, the team of Dr. Yuval Rinkevich, Group Leader for Regenerative Biology at the Institute of Lung Biology and Disease at Helmholtz Zentrum München, aimed to finally find an answer. As it was already known that all scars derive from a fibroblast lineage expressing the Engrailed-1 gene - a lineage not only present in skin, but also in fascia - the researchers intentionally tried to understand whether or not fascia might be the origin of fibroblasts.

Fibroblasts kit - ready to heal wounds

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

The Future of Work

03.12.2019 | Event News

First International Conference on Agrophotovoltaics in August 2020

15.11.2019 | Event News

Laser Symposium on Electromobility in Aachen: trends for the mobility revolution

15.11.2019 | Event News

 
Latest News

City research draws on Formula 1 technology for the construction of skyscrapers

10.12.2019 | Architecture and Construction

Reorganizing a computer chip: Transistors can now both process and store information

10.12.2019 | Information Technology

Could dark carbon be hiding the true scale of ocean 'dead zones'?

10.12.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>